Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia

Vaccine

Volumn 30, Issue 33, 2012, Pages 4977-4982

  Sutherland, Marjorie D ^a   Goodyear, Andrew W ^a   Troyer, Ryan M ^a   Chandler, Jeffrey C ^a   Dow, Steven W ^a   Belisle, John T ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Antibodies; Francisella tularensis; Membrane proteins

Indexed keywords

FRANCISELLA TULARENSIS MEMBRANE PROTEIN ANTIGEN; GENTAMICIN; TULAREMIA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION PREVENTION; LOW DRUG DOSE; LUNG INFECTION; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; TULAREMIA;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL LOAD; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; FEMALE; FRANCISELLA TULARENSIS; GENTAMICINS; LIVER; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; POST-EXPOSURE PROPHYLAXIS; SPLEEN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TULAREMIA; VACCINATION;

EID: 84862771042     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.037     Document Type: Article

References (37)

1. Saslaw S., Eigelsbach H.T., Wilson H.E., Prior J.A., Carhart S. Tularemia vaccine study. I. Intracutaneous challenge. Arch Intern Med 1961, 107:689-701.
2. Saslaw S., Eigelsbach H.T., Prior J.A., Wilson H.E., Carhart S. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med 1961, 107:702-714.
3. Dennis D.T., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001, 285(21):2763-2773.
4. Petersen J.M., Schriefer M.E. Tularemia: emergence/re-emergence. Vet Res 2005, 36(3):455-467.
5. Mason W.L., Eigelsbach H.T., Little S.F., Bates J.H. Treatment of tularemia, including pulmonary tularemia, with gentamicin. Am Rev Respir Dis 1980, 121(1):39-45.
6. Piercy T., Steward J., Lever M.S., Brooks T.J. In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice. J Antimicrob Chemother 2005, 56(6):1069-1073.
7. Steward J., Piercy T., Lever M.S., Simpson A.J., Brooks T.J. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. Int J Antimicrob Agents 2006, 27(5):439-443.
8. Russell P., Eley S.M., Fulop M.J., Bell D.L., Titball R.W. The efficacy of ciprofloxacin and doxycycline against experimental tularaemia. J Antimicrob Chemother 1998, 41(4):461-465.
9. Scheel O., Reiersen R., Hoel T. Treatment of tularemia with ciprofloxacin. Eur J Clin Microbiol Infect Dis 1992, 11(5):447-448.
10. Harrell R.E., Whitaker G.R. Tularemia: emergency department presentation of an infrequently recognized disease. Am J Emerg Med 1985, 3(5):415-418.
11. Risi G.F., Pombo D.J. Relapse of tularemia after aminoglycoside therapy: case report and discussion of therapeutic options. Clin Infect Dis 1995, 20(1):174-175.
12. Miller S.D., Snyder M.B., Kleerekoper M., Grossman C.H. Ulceroglandular tularemia: a typical case of relapse. Henry Ford Hosp Med J 1989, 37(2):73-75.
13. Penn R.L., Kinasewitz G.T. Factors associated with a poor outcome in tularemia. Arch Intern Med 1987, 147(2):265-268.
14. Kaya A., Uysal I.O., Guven A.S., Engin A., Gulturk A., Icagasioglu F.D., et al. Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia. Med Sci Monit 2011, 17(7):CR376-CR380.
15. Maurin M., Mersali N.F., Raoult D. Bactericidal activities of antibiotics against intracellular Francisella tularensis. Antimicrob Agents Chemother 2000, 44(12):3428-3431.
16. Pacifici G.M. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur J Clin Pharmacol 2009, 65(4):419-427.
17. Pammit M.A., Budhavarapu V.N., Raulie E.K., Klose K.E., Teale J.M., Arulanandam B.P. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother 2004, 48(12):4513-4519.
18. Onyeji C.O., Bui K.Q., Nicolau D.P., Nightingale C.H., Bow L., Quintiliani R. Influence of adjunctive interferon-gamma on treatment of gentamicin- and vancomycin-resistant Enterococcus faecalis infection in mice. Int J Antimicrob Agents 1999, 12(4):301-309.
19. Propst K.L., Troyer R.M., Kellihan L.M., Schweizer H.P., Dow S.W. Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrob Agents Chemother 2010, 54(5):1785-1792.
20. Drabick J.J., Narayanan R.B., Williams J.C., Leduc J.W., Nacy C.A. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. Am J Med Sci 1994, 308(2):83-87.
21. Mara-Koosham G., Hutt J.A., Lyons C.R., Wu T.H. Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains. Infect Immun 2011, 79(4):1770-1778.
22. Kirimanjeswara G.S., Golden J.M., Bakshi C.S., Metzger D.W. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 2007, 179(1):532-539.
23. Fulop M., Manchee R., Titball R. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 1995, 13(13):1220-1225.
24. Huntley J.F., Conley P.G., Rasko D.A., Hagman K.E., Apicella M.A., Norgard M.V. Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun 2008, 76(8):3664-3671.
25. Huntley J.F., Conley P.G., Hagman K.E., Norgard M.V. Characterization of Francisella tularensis outer membrane proteins. J Bacteriol 2007, 189(2):561-574.
26. Ireland R., Olivares-Zavaleta N., Warawa J.M., Gherardini F.C., Jarrett C., Hinnebusch B.J., et al. Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS Pathog 2010, 6(5):e1000921.
27. Chandler J.C., Molins C.R., Petersen J.M., Belisle J.T. Differential chitinase activity and production within Francisella species, subspecies, and subpopulations. J Bacteriol 2011, 193(13):3265-3275.
28. Henderson A., Propst K., Kedl R., Dow S. Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity. Vaccine 2011, 29(32):5304-5312.
29. Frey A., Di Canzio J., Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998, 221(1-2):35-41.
30. Fulop M., Mastroeni P., Green M., Titball R.W. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 2001, 19(31):4465-4472.
31. Parker R.T., Lister L.M., Bauer R.E., Hall H.E., Woodward T.E. Use of chloramphenicol (chloromycetin) in experimental and human tularemia. J Am Med Assoc 1950, 143(1):7-11.
32. Tulkens P., Trouet A. The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts. Biochem Pharmacol 1978, 27(4):415-424.
33. Chandler J.C. The surface proteome of Francisella tularensis 2011, Colorado State University.
34. Hood A.M. Virulence factors of Francisella tularensis. J Hyg (Lond) 1977, 79(1):47-60.
35. Balagopal A., MacFarlane A.S., Mohapatra N., Soni S., Gunn J.S., Schlesinger L.S. Characterization of the receptor-ligand pathways important for entry and survival of Francisella tularensis in human macrophages. Infect Immun 2006, 74(9):5114-5125.
36. Geier H., Celli J. Phagocytic receptors dictate phagosomal escape and intracellular proliferation of Francisella tularensis. Infect Immun 2011, 79(6):2204-2214.
37. Clay C.D., Soni S., Gunn J.S., Schlesinger L.S. Evasion of complement-mediated lysis and complement C3 deposition are regulated by Francisella tularensis lipopolysaccharide O antigen. J Immunol 2008, 181(8):5568-5578.